HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by YLIKORKALA, O. Articles by VIINIKKA, L. Search for Related Content PubMed PubMed Citation Articles by YLIKORKALA, O. Articles by VIINIKKA, L.

Effect of Cytostatics on Prostaglandin F₂ Prostacyclin, and Thromboxane in Patients with Gynecologic Malignancies

From the Departments of Obstetrics and Gynecology and of Clinical Chemistry, University of Oulu, Oulu, Finland

Abstract

Serial measurements of 6-keto-PGF₁ (a stable metabolite of prostacyclin), thromboxane B₂ (TxB₂, a stable metabolite of thromboxane A₂), and 13,14-dihydro-15-keto-PGF₂ (MPGF₂, a stable metabolite of prostaglandin F₂) were made from plasma of 9 women with metastatic ovarian or uterine malignancies before and after the combined administration of doxorubicin, cyclophosphamide, 5-fluorouracil, and cisplatinum. Elevated basal levels of TxB₂ were detected in all patients, elevated levels of 6-keto-PGF₂ in 5 patients, and elevated levels of M-PGF₂ in 3 patients. The use of chemotherapy was accompanied by a significant increase of 37% (P<.01) in the M-PGF₂ level on the day after treatment and by significant decreases of 30 to 40% (P<.05) in 6-keto-PGF₁ and TxB₂levels, which became apparent immediately after the treatment and persisted for 3 to 5 days. Thus, malignancies may be accompanied by increased production of prostacyclin and thromboxane A₂, which can be lowered by cytostatics. (Obstet Gynecol 58:483, 1981)